HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer

Authors:

Abstract
Advanced prostate cancer treatment with androgen deprivation therapy (ADT) via medical or surgical castration depletes circulating gonadal testosterone levels and nearly always produces initial clinical responses. However, castration-resistant prostate cancer (CRPC) eventually develops, typically by revived signaling through the androgen receptor pathway.1 A major mechanism of androgen receptor restimulation is tumor synthesis of testosterone or dihydrotestosterone from extragonadal precursor steroids, including adrenal dehydroepiandrosterone and its respective sulfate.2 The critical role of precursor steroids has been clinically validated by the survival benefit conferred by abiraterone, which blocks extragonadal androgen synthesis by inhibiting 17α-hydroxylase/17,20-lyase.3,4

This publication has 38 references indexed in Scilit: